Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PhoreMost, Otsuka Enter Drug Discovery Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

PhoreMost, Otsuka Enter Drug Discovery Alliance

Will leverage PhoreMost’s phenotypic screening platform, SITESEEKER, to identify novel targets for Otsuka’s discovery programs

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

PhoreMost Ltd., a UK-based biopharma company dedicated to drugging ‘undruggable’ disease targets, has entered into a multi-project collaboration with Otsuka Pharmaceutical Co. Financial details were not disclosed.

PhoreMost will leverage its expertise and next-gen phenotypic screening platform, SITESEEKER, for disease relevant pathways selected by Otsuka. Novel targets identified will be further validated and characterized by Otsuka as part of its development pipeline, with an initial focus on gene therapy applications of identified targets.

PhoreMost’s SITESEEKER platform exploits protein shape diversity to find functionally active peptides, significantly enhancing the power of phenotypic screening and translation into therapeutic modalities. Based on proprietary protein interference, or ‘PROTEINi’, technology PhoreMost uses SITESEEKER to probe the entire proteome in a live cell environment for novel druggable targets linked to any chosen disease. This enables the systematic discovery of functionally active peptides which are directly linked to useful therapeutic applications.

Dr. Chris Torrance, chief executive officer of PhoreMost, said, “This collaboration with Otsuka is further recognition of the power of the SITESEEKER approach to drive the identification of novel, druggable targets. We are particularly excited to be exploring not only small molecule therapeutics but also gene therapy applications of our platform.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics